| Regimen . | Patients, n . | RR, % . | mPFS, mos . | MST, mos . |
|---|---|---|---|---|
| Platinum‐based doublets | 178 | 38.2 | N/A | 30.7 |
| CBDCA + PTX | 70 | 40.0 | 9.1 | 27.8 |
| CDDP + VP‐16 | 35 | 48.6 | 8.1 | 35.0 |
| CBDCA + AMR | 17 | 11.8 | N/A | 51.9 |
| CDDP + CPT‐11 | 16 | 66.7 | 8.7 | 27.2 |
| CBDCA + VP‐16 | 15 | 30.8 | 8.4 | 16.8 |
| CDDP + DTX | 9 | 22.2 | 6.0 | 33.3 |
| Other | 16 | N/A | N/A | N/A |
| Other multidrug chemotherapy | 98 | 42.7 | N/A | 29.9 |
| ADOC | 79 | 41.0 | 6.7 | 29.9 |
| PAC | 8 | 37.5 | 30.8 | 42.4 |
| Other | 11 | N/A | N/A | N/A |
| Single agent | 10 | 44.4 | N/A | 54.9 |
| All regimens | 286 | 40.0 | N/A | 30.7 |
| Regimen . | Patients, n . | RR, % . | mPFS, mos . | MST, mos . |
|---|---|---|---|---|
| Platinum‐based doublets | 178 | 38.2 | N/A | 30.7 |
| CBDCA + PTX | 70 | 40.0 | 9.1 | 27.8 |
| CDDP + VP‐16 | 35 | 48.6 | 8.1 | 35.0 |
| CBDCA + AMR | 17 | 11.8 | N/A | 51.9 |
| CDDP + CPT‐11 | 16 | 66.7 | 8.7 | 27.2 |
| CBDCA + VP‐16 | 15 | 30.8 | 8.4 | 16.8 |
| CDDP + DTX | 9 | 22.2 | 6.0 | 33.3 |
| Other | 16 | N/A | N/A | N/A |
| Other multidrug chemotherapy | 98 | 42.7 | N/A | 29.9 |
| ADOC | 79 | 41.0 | 6.7 | 29.9 |
| PAC | 8 | 37.5 | 30.8 | 42.4 |
| Other | 11 | N/A | N/A | N/A |
| Single agent | 10 | 44.4 | N/A | 54.9 |
| All regimens | 286 | 40.0 | N/A | 30.7 |
Abbreviations: ADOC, cisplatin/doxorubicin/vincristine/cyclophosphamide; AMR, amrubicin; CBDCA, carboplatin; CDDP, cisplatin; CPT‐11, irinotecan; DTX, docetaxel; mos, months; mPFS, median progression‐free survival; MST, median survival time; N/A, not analyzed; PAC, cisplatin/doxorubicin/cyclophosphamide; PTX, paclitaxel; RR, response rate; VP‐16, etoposide.
| Regimen . | Patients, n . | RR, % . | mPFS, mos . | MST, mos . |
|---|---|---|---|---|
| Platinum‐based doublets | 178 | 38.2 | N/A | 30.7 |
| CBDCA + PTX | 70 | 40.0 | 9.1 | 27.8 |
| CDDP + VP‐16 | 35 | 48.6 | 8.1 | 35.0 |
| CBDCA + AMR | 17 | 11.8 | N/A | 51.9 |
| CDDP + CPT‐11 | 16 | 66.7 | 8.7 | 27.2 |
| CBDCA + VP‐16 | 15 | 30.8 | 8.4 | 16.8 |
| CDDP + DTX | 9 | 22.2 | 6.0 | 33.3 |
| Other | 16 | N/A | N/A | N/A |
| Other multidrug chemotherapy | 98 | 42.7 | N/A | 29.9 |
| ADOC | 79 | 41.0 | 6.7 | 29.9 |
| PAC | 8 | 37.5 | 30.8 | 42.4 |
| Other | 11 | N/A | N/A | N/A |
| Single agent | 10 | 44.4 | N/A | 54.9 |
| All regimens | 286 | 40.0 | N/A | 30.7 |
| Regimen . | Patients, n . | RR, % . | mPFS, mos . | MST, mos . |
|---|---|---|---|---|
| Platinum‐based doublets | 178 | 38.2 | N/A | 30.7 |
| CBDCA + PTX | 70 | 40.0 | 9.1 | 27.8 |
| CDDP + VP‐16 | 35 | 48.6 | 8.1 | 35.0 |
| CBDCA + AMR | 17 | 11.8 | N/A | 51.9 |
| CDDP + CPT‐11 | 16 | 66.7 | 8.7 | 27.2 |
| CBDCA + VP‐16 | 15 | 30.8 | 8.4 | 16.8 |
| CDDP + DTX | 9 | 22.2 | 6.0 | 33.3 |
| Other | 16 | N/A | N/A | N/A |
| Other multidrug chemotherapy | 98 | 42.7 | N/A | 29.9 |
| ADOC | 79 | 41.0 | 6.7 | 29.9 |
| PAC | 8 | 37.5 | 30.8 | 42.4 |
| Other | 11 | N/A | N/A | N/A |
| Single agent | 10 | 44.4 | N/A | 54.9 |
| All regimens | 286 | 40.0 | N/A | 30.7 |
Abbreviations: ADOC, cisplatin/doxorubicin/vincristine/cyclophosphamide; AMR, amrubicin; CBDCA, carboplatin; CDDP, cisplatin; CPT‐11, irinotecan; DTX, docetaxel; mos, months; mPFS, median progression‐free survival; MST, median survival time; N/A, not analyzed; PAC, cisplatin/doxorubicin/cyclophosphamide; PTX, paclitaxel; RR, response rate; VP‐16, etoposide.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
